What is RZLT's market cap?

$383.02M, based on the Nov 4 close of $3.96.

Does Rezolute, Inc. Common Stock (NV) pay a dividend?

No regular cash dividend has been paid in the last year.

How much of RZLT is sold short?

19.2M shares, 22.5% of float, as of Oct 15, 2026.

What sector is RZLT in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · RZLTHealthcarePharmaceuticals

Rezolute, Inc. Common Stock (NV) (RZLT)

$3.96−1.25%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$4.01▼ 55.93% in range

Nov 3, 2025Low $1.40 · High $10.94Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

Rezolute, Inc. Common Stock (NV) closed at $3.96 on Nov 4, down 1.25%, 63.8% below its 52-week closing high. Volume of 1.1M shares was 0.78× its 20-day average (below normal).

Split-adjusted performance: -8.3% over one month, +26.1% over six months, -56.5% over one year.

Short interest was 19.2M shares at the Oct 15 settlement, up 14.7% from the prior report (22.5% of float, 10.1 days to cover).

Market cap$383.0M96.7M shares

Revenue · quarter$0.00—

Diluted EPS$-0.20—

P/E · TTM—

Net margin—

Dividend yieldNone

52-week range1.40 – 10.94−63.8% from high

Volume1.1M0.78× 20-day avg

Volatility · 60d60.1%Annualised

Short % of float22.5%10.1 days to cover

Net cash$107.8MCash $107.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −6.2%1M −8.3%3M −15.7%6M +26.1%YTD +67.8%1Y −56.5%3Y +277.1%5Y −39.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum85

Revenue growth—

Net margin—

Value (low P/E)—

Size57

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short19.2M+14.7% vs prior

Days to cover10.1Settled Oct 15

% of float22.5%

Short vol. 10d37.4%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
RZLTRezolute, Inc. Common Stock (NV)	$3.96	−1.25%	+26.1%	—	—	—	$383.0M
AVTXAvalo Therapeutics	$7.07	−2.48%	−67.6%	—	—	—	$379.2M	Compare
LYELLyell Immunopharma	$15.43	+43.27%	−26.0%	−50.0%	−1118875.0%	—	$378.1M	Compare
MPLTMapLight Therapeutics	$6.71	−1.47%	−76.9%	—	—	—	$372.9M	Compare
BLSMBlossomHill Therapeutics	$12.38	−0.24%	—	—	—	—	$393.5M	Compare
CTNMContineum Therapeutics	$9.79	+1.03%	−34.5%	—	—	—	$368.3M	Compare
ASMBAssembly Biosciences	$19.87	−0.25%	−36.6%	+38.9%	−28.8%	—	$404.6M	Compare
AVIRAtea Pharmaceuticals	$4.46	+6.95%	−21.1%	—	—	—	$357.7M	Compare
ALTAltimmune	$2.12	+3.92%	−35.0%	−100.0%	—	—	$412.4M	Compare

News about Rezolute, Inc. Common Stock (NV)

All news →

Rezolute to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · May 11, 2026▲ Positive Rezolute, Inc. Investigated by the Portnoy Law FirmGlobeNewswire Inc. · Apr 24, 2026▼ Negative Rezolute to Participate in the Citizens Life Sciences ConferenceGlobeNewswire Inc. · Mar 4, 2026Neutral

Quick answers

What does Rezolute, Inc. Common Stock (NV) do?: Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.
What is RZLT's market cap?: $383.02M, based on the Nov 4 close of $3.96.
Does Rezolute, Inc. Common Stock (NV) pay a dividend?: No regular cash dividend has been paid in the last year.
How much of RZLT is sold short?: 19.2M shares, 22.5% of float, as of Oct 15, 2026.
What sector is RZLT in?: Healthcare, in the Pharmaceuticals industry.

About Rezolute, Inc. Common Stock (NV)

Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company.

HQ: Redwood City, CA58 employeesListed Dec 23, 2011rezolutebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology